In 2007, ES Cell International Pte. Ltd. (ESI) announced the world’s first human embryonic stem (hES) cell lines derived according to the principles of current good manufacturing process (cGMP). ESI’s clinical-grade master cell banks may be used to generate clonal clinical-grade embryonic progenitor cell lines with a level of purity and quality unsurpassed in the industry.
BioTime acquired ESI in May 2010. We expect that the acquisition of ESI’s clinical-grade hES cell bank will save years of development time and thereby accelerate the development of clinical-grade progenitor cells for potential use as research and therapeutic products.